Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.06
+0.09 (0.32%)
as of Aug 25, 2026, 2:11:02 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Aug 27, 2003
Likes the company at these levels. Their recent merger will create growth. There should be 13/14% growth in earnings over the next couple of years.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$29.91

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2003
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.The strongest of the drug companies and the deepest pipeline.A good price to buy out for the long-term.
Photo of Matt BaraschMatt BaraschUnlock Rating
$29.55

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 18, 2003
(A top pick July 23/03.Down 4 «%.)Drug companies , stocks have dropped because they think of concerns on drug pricing.Longer-term demographically Phizer is very well-positioned.It represents great long-term value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$31.47

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 12, 2003
Model price is around $29.Prefers Merk.Too expensive.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$32.87

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 07, 2003
Likes this company.Valuation is more attractive than what it has been for some time.Generating growth, and very little risk in the stock.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$32.94

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 24, 2003
Good company. Pharmaceutical group is reasonably well priced. Compatition is coming into their core product line.
Photo of Ian AinsworthIan Ainsworth
Owned
Unlock Rating
$32.55

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 23, 2003
15/25% earnings growth for the next 3/5 years. High quality.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$32.93

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 22, 2003
Ethical drug companies are not doing well at this time.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$32.43

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 17, 2003
Has the deepest and broadest portfolio of any drug company. 20 drugs under development. Growth may be limited.
Photo of Brad WillockBrad Willock
Owned
Unlock Rating
$32.76

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 15, 2003
Has a huge pipeline. PE is at a reasonable level. Good dividends and they are increasing.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$33.86

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 10, 2003
Fair market value is excellant. Investors like drug stocks.
Photo of Ross HealyRoss HealyUnlock Rating
$33.66

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 02, 2003
If you own it, don't let it make new lows on you. Trend is moving higher.
Photo of Bill CarriganBill CarriganUnlock Rating
$34.65

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 19, 2003
All drug companies offer good value right now. Prefers Bristol Myers Squibb.
Photo of Ray SteeleRay SteeleUnlock Rating
$35.60

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 13, 2003
US is making progress on a medicare drug plan. 17 X this years earnings and 16 X next. Great pipeline. The stock has underperformed.A lot of free cash flow.
Photo of Laura WallaceLaura WallaceUnlock Rating
$33.08

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 11, 2003
US pharmaceuticals are looking cheaper than they have in some time.
Photo of John ZechnerJohn ZechnerUnlock Rating
$33.28

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 766 to 780 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like